HC Wainwright Increases Earnings Estimates for XOMA Royalty

XOMA Royalty Corporation (NASDAQ:XOMA) – Equities researchers at HC Wainwright raised their FY2026 EPS estimates for XOMA Royalty in a research note issued on Thursday, August 21st. HC Wainwright analyst J. Pantginis now forecasts that the biotechnology company will post earnings of $1.34 per share for the year, up from their prior estimate of $1.16. HC Wainwright currently has a “Buy” rating and a $104.00 target price on the stock. The consensus estimate for XOMA Royalty’s current full-year earnings is ($1.41) per share.

XOMA Royalty (NASDAQ:XOMA) last issued its quarterly earnings results on Wednesday, August 13th. The biotechnology company reported $0.48 EPS for the quarter, topping analysts’ consensus estimates of ($0.12) by $0.60. The company had revenue of $13.13 million for the quarter, compared to analyst estimates of $9.39 million. XOMA Royalty had a negative net margin of 27.57% and a positive return on equity of 2.63%.

Several other research firms have also issued reports on XOMA. Zacks Research upgraded shares of XOMA Royalty to a “hold” rating in a report on Tuesday, August 12th. Wall Street Zen upgraded shares of XOMA Royalty from a “hold” rating to a “buy” rating in a report on Monday, August 11th. Two equities research analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the company’s stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average price target of $69.50.

XOMA Royalty Price Performance

XOMA stock opened at $34.20 on Friday. The firm has a market cap of $413.48 million, a price-to-earnings ratio of -22.06 and a beta of 1.00. The company has a quick ratio of 4.88, a current ratio of 4.88 and a debt-to-equity ratio of 1.41. XOMA Royalty has a 12-month low of $18.35 and a 12-month high of $35.00. The company’s fifty day simple moving average is $27.20 and its 200 day simple moving average is $24.58.

Institutional Investors Weigh In On XOMA Royalty

Several hedge funds and other institutional investors have recently bought and sold shares of XOMA. JPMorgan Chase & Co. increased its stake in XOMA Royalty by 238.9% in the fourth quarter. JPMorgan Chase & Co. now owns 12,089 shares of the biotechnology company’s stock valued at $318,000 after purchasing an additional 8,522 shares in the last quarter. Wells Fargo & Company MN boosted its stake in XOMA Royalty by 38.0% in the fourth quarter. Wells Fargo & Company MN now owns 4,300 shares of the biotechnology company’s stock valued at $113,000 after acquiring an additional 1,183 shares during the last quarter. Renaissance Technologies LLC boosted its stake in XOMA Royalty by 89.8% in the fourth quarter. Renaissance Technologies LLC now owns 16,100 shares of the biotechnology company’s stock valued at $423,000 after acquiring an additional 7,619 shares during the last quarter. Barclays PLC boosted its stake in XOMA Royalty by 13.6% in the fourth quarter. Barclays PLC now owns 12,784 shares of the biotechnology company’s stock valued at $336,000 after acquiring an additional 1,528 shares during the last quarter. Finally, Northern Trust Corp boosted its stake in XOMA Royalty by 1.5% in the fourth quarter. Northern Trust Corp now owns 91,181 shares of the biotechnology company’s stock valued at $2,396,000 after acquiring an additional 1,340 shares during the last quarter. 95.92% of the stock is owned by institutional investors.

XOMA Royalty Company Profile

XOMA Corporation operates as a biotech royalty aggregator in the United States and the Asia Pacific. It has a portfolio of economic rights to future potential milestone and royalty payments associated with partnered commercial and pre-commercial therapeutic candidates. The company also focuses on early to mid-stage clinical assets primarily in Phase 1 and 2 with commercial sales potential that are licensed to partners; and acquires milestone and royalty revenue streams on late-stage clinical or commercial assets.